8-K: Plus Therapeutics Reports Q4 and Full Year 2024 Financial Results, Highlights $15 Million Financing and CNSide Launch

Plus Therapeutics announces its Q4 and full year 2024 financial results, highlighting a $15 million financing round and the upcoming commercial launch of its CNSide diagnostic platform.

Summary

• Plus Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company raised $15 million in a private placement, regaining Nasdaq compliance and extending its financial runway into 2026.
• A $2.0 million grant award advance was received from CPRIT to accelerate REYOBIQ development for leptomeningeal metastases (LM).
• Key leadership appointments were made, including Dr. Michael Rosol as Chief Development Officer and Mr. Russell Bradley as President and General Manager of CNSide Diagnostics, LLC.
• The FDA agreed to the brand name REYOBIQ (Rhenium Re186 Obisbemeda) for the company's lead radiotherapeutic.
• Phase 1 clinical trial results for REYOBIQ in recurrent glioblastoma (GBM) were published, demonstrating safety and potential efficacy.
• The company completed the ReSPECT-LM Phase 1 single dose administration trial and determined the maximum feasible and recommended Phase 2 doses.
• Positive ReSPECT-LM Phase 1 interim data for LM and breast cancer patients with LM were presented at medical conferences.
• A strategic agreement with Telix IsoTherapeutics Group was expanded to secure a reliable supply of cGMP Rhenium-186.
• Positive FORESEE clinical trial summary data was presented, demonstrating the utility of the CNSide Cerebrospinal Fluid Assay Platform.
• The company plans a full commercial launch of CNSide in 2025.
• Cash and investments balance was $3.6 million at December 31, 2024, compared to $8.6 million at December 31, 2023.
• Grant revenue was $5.8 million for the year ending December 31, 2024, and $4.9 million for the year ending December 31, 2023.
• Total operating loss for the year ending December 31, 2024, was $14.7 million versus $13.3 million for the year ending December 31, 2023.
• Net loss for the year ending December 31, 2024, was $13.0 million, or $(1.95) per basic share versus $13.3 million, or $(4.24) per basic share, for the year ending December 31, 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the successful financing, clinical progress, and upcoming commercial launch, but tempered by the increased operating loss and decreased cash position.

Positives

• The $15 million private placement provides financial stability and extends the company's runway.
• The CPRIT grant supports the development of REYOBIQ for leptomeningeal metastases.
• FDA agreement on the REYOBIQ brand name is a positive step towards commercialization.
• Positive Phase 1 clinical trial results for REYOBIQ in GBM show promising efficacy.
• The upcoming commercial launch of CNSide represents a potential revenue stream for the company.
• The strategic agreement with Telix IsoTherapeutics Group secures a reliable supply of cGMP Rhenium-186.

Negatives

• The company's cash and investments balance decreased from $8.6 million in 2023 to $3.6 million in 2024.
• The total operating loss increased from $13.3 million in 2023 to $14.7 million in 2024.
• The company reported a net loss of $13.0 million for the year ending December 31, 2024.

Risks

• The company's product candidates and therapies are in the early stages of development.
• Clinical trials of the company's product candidates and therapies may not be successful.
• The company may face challenges in raising additional cash.
• The company may face challenges in developing and protecting its intellectual property.
• The company may face challenges associated with radiotherapeutic manufacturing, production, and distribution.

Future Outlook

The company anticipates transitioning to an operational revenue-generating company with the launch of CNSide in 2025 and progressing therapeutic programs to key clinical and regulatory milestones.

Management Comments

• Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs, said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.
• The recently raised capital, coupled with existing grant support, enables us to progress both our therapeutic programs to key clinical and regulatory milestones as well as commercially launch our CNSide diagnostic platform.
• The year 2025 has the potential to be transformational at Plus as we anticipate transitioning to an operational revenue generating company with the launch of CNSide.
• We are highly appreciative of our investors, partners and other stakeholders for their continued commitment to Plus as we deliver on our objectives and drive value.

Industry Context

Plus Therapeutics is operating in the competitive field of cancer therapeutics and diagnostics, focusing on targeted radiotherapeutics for central nervous system cancers. The company's focus on rare cancers and CNS delivery differentiates it from competitors.

Comparison to Industry Standards

• The median overall survival of 17 months in recurrent glioblastoma (GBM) patients receiving a radiation dose >100 Gy in the REYOBIQ Phase 1 trial is compared to the standard of care, suggesting a potential improvement.
• Telix IsoTherapeutics Group is a comparable company in the radiopharmaceutical space, and the expanded agreement with them is a positive sign for Plus Therapeutics' supply chain.
• CNSide is a proprietary laboratory-developed test, such as CNSide, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, which is a growing area of interest in cancer diagnostics.

Management Changes

Stakeholder Impact

• Shareholders: The $15 million financing and potential revenue from CNSide could positively impact shareholder value.
• Employees: The strengthened management team and progress in clinical trials could improve employee morale and job security.
• Patients: The development of REYOBIQ and CNSide could provide new treatment and diagnostic options for patients with CNS cancers.
• Partners: The expanded agreement with Telix IsoTherapeutics Group strengthens the supply chain for REYOBIQ.

Next Steps

• Full commercial launch of CNSide in 2025.
• Presentations at upcoming medical conferences.
• Complete enrollment of Cohort 1 in the ReSPECT-LM Phase 1 multiple dose administration trial in 2025.
• Complete end of Phase 1 meeting with the U.S. FDA for the ReSPECT-LM trial and determine next clinical steps in 2025.
• Complete ReSPECT-GBM Phase 2 enrollment in 2025.
• Obtain IND approval for the ReSPECT-PBC Phase 1/2 trial of REYOBIQ for pediatric ependymoma and high-grade glioma in H2 2025.

Key Dates

Keywords

REYOBIQ, CNSide, Plus Therapeutics, Radiotherapeutics, Glioblastoma, Leptomeningeal Metastases, Financial Results, Clinical Trials, Cancer, Oncology